AGILENT RECEIVES FDA APPROVAL FOR PD-L1 IHC 28-8 PHARMDX IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), GASTRIC, GASTROESOPHAGEAL JUNCTION (GEJ), AND ESOPHAGEAL ADENOCARCINOMA

Reuters · 1d ago

Please log in to view news